Search Filters
Advanced Search
SMC ID Date Medicine Submission Type Indication
SMC2903 12/10/2026 obinutuzumab (Gazyvaro) Full

In combination with mycophenolate mofetil (MMF) for the treatment of adult patients with active Class III or IV, with or without concomitant Class V, lupus nephritis (LN).
SMC2893 13/04/2026 acalabrutinib (Calquence) Abbreviated

In combination with venetoclax with or without obinutuzumab for the treatment of adult patients with previously untreated chronic lymphocytic leukaemia (CLL).
SMC2671 13/05/2024 zanubrutinib (Brukinsa) Non submission

In combination with obinutuzumab for the treatment of adult patients with refractory or relapsed follicular lymphoma (FL) who have received at least two prior systemic therapies.
SMC2427 09/05/2022 venetoclax (Venclyxto) Full

In combination with obinutuzumab (VenG) is indicated for the treatment of adult patients with previously untreated chronic lymphocytic leukaemia (CLL).
SMC2347 07/06/2021 acalabrutinib (Calquence) Full

As monotherapy or in combination with obinutuzumab for the treatment of adult patients with previously untreated chronic lymphocytic leukaemia (CLL)
SMC2346 12/04/2021 acalabrutinib (Calquence) Abbreviated

As monotherapy or in combination with obinutuzumab for the treatment of adult patients with previously untreated chronic lymphocytic leukaemia (CLL)
SMC2293 07/12/2020 venetoclax (Venclyxto) Full

In combination with obinutuzumab (VenG) is indicated for the treatment of adult patients with previously untreated chronic lymphocytic leukaemia (CLL).
SMC2244 11/11/2019 ibrutinib (Imbruvica) Non submission

In combination with obinutuzumab for the treatment of adult patients with previously untreated chronic lymphocytic leukaemia.
SMC2015 10/09/2018 obinutuzumab (Gazyvaro) Resubmission In combination with chemotherapy, followed by maintenance therapy in patients achieving a response, for the treatment of patients with previously untreated advanced follicular lymphoma (FL).
1219/17 13/03/2017 obinutuzumab (Gazyvaro) Full In combination with bendamustine followed by obinutuzumab maintenance is indicated for the treatment of patients with follicular lymphoma who did not respond or who progressed during or up to six months after treatment with rituximab or a rituximab-containing regimen.
1008/14 08/12/2014 obinutuzumab (Gazyvaro) Full

In combination with chlorambucil, obinutuzumab is indicated for the treatment of adult patients with previously untreated chronic lymphocytic leukaemia (CLL) and with comorbidities making them unsuitable for full-dose fludarabine based therapy.

No medicines have been found.